Ardelyxincis A Biopharmaceutical Company Based In Fremontcaliforniawith A Focus On Discoveringdevelopingand Commercializing Innovative Medicinesfounded In 2007Ardelyx Aims To Address Significant Unmet Medical Needsparticularly In Kidney Diseasescardiorenal Conditionsand Gastrointestinal Disordersthe Company Emphasizes A Mission To Improve Patient Lives Through First In Class Therapies Ardelyx Has Developed Key Productsincluding Tenapanoribsrelafor Irritable Bowel Syndrome With Constipationrdx013 For Hyperkalemiaand Rdx7675 For Chronic Kidney Diseasethe Company Is Committed To Research And Developmentinvesting $84 2 Million In 2023 And Conducting Three Ongoing Clinical Trials To Advance Its Product Pipelineardelyx S Core Values Highlight A Collaborative And Innovative Approach To Science And Patient Carereflecting Its Dedication To Serving Underserved Populations In Healthcare
